Portage Biotech, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Public
- Established
- 1973-01-01
- Employees
- 7
- Market Cap
- $6.7M
Adenosine Antagonists Show Promise in Clinical Trials for Cancer and COPD
• Adenosine antagonists are under investigation for novel therapeutic applications in neurodegenerative diseases, oncology, and cardiovascular disorders.
• Several companies, including Arcus Biosciences and Corvus Pharmaceuticals, are advancing adenosine antagonists through clinical trials to improve treatment landscapes.
• Clinical trials are evaluating drugs like etrumadenant, ciforadenant and PBF-680 in various phases for conditions like colorectal cancer, prostate cancer and COPD.
Kronos Bio Halts Istisociclib Development, Considers Strategic Alternatives
• Kronos Bio discontinued istisociclib (KB-0742) development after safety concerns arose in a Phase I/II trial for platinum-resistant high-grade serous ovarian cancer.
• The trial revealed neurological adverse events in five of seven patients, leading to treatment discontinuation or dosage reduction in some participants.
• Facing financial pressures, Kronos Bio is exploring strategic alternatives, including acquisition or merger, to maximize stockholder value and preserve cash.
• The company is also seeking partnerships for preclinical assets KB-9558 and KB-7898, while focusing on IND application for multiple myeloma and autoimmune disorders.
© Copyright 2025. All Rights Reserved by MedPath